Nutlin-3

For research use only. Not for use in humans.

目录号：S1061

CAS No. 890090-75-2

Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1515.15	现货
5mg	RMB 900.36	现货
25mg	RMB 3026.07	现货
50mg	RMB 5298.93	现货
100mg	RMB 7939.67	现货
200mg	RMB 13243.23	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Nutlin-3发表文献68篇：

Nat Cell Biol, 2021, 23(6):595-607

PubMed: 34108663 ( click the link to review the publication )

Cell Stem Cell, 2018, 23(4):544-556

PubMed: 30244867 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Sci Adv, 2021, 7(32)eabf7561

PubMed: 34348895 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3481

PubMed: 34108482 ( click the link to review the publication )

Elife, 2021, 10e61630

PubMed: 33459596 ( click the link to review the publication )

Cell Death Dis, 2021, 12(7):640

PubMed: 34162828 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):1

PubMed: 33414393 ( click the link to review the publication )

Eur J Med Chem, 2021, 217:113359

PubMed: 33725632 ( click the link to review the publication )

Cancer Immunol Immunother, 2021, 10.1007/s00262-021-02940-5

PubMed: 33866408 ( click the link to review the publication )

Sci Rep, 2021, 11(1):14253

PubMed: 34244565 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00730-4

PubMed: 34216619 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00965-0

PubMed: 34481841 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Clin Cancer Res, 2020, 26(1):122-134

PubMed: 31767563 ( click the link to review the publication )

Cell Rep, 2020, 30(2):497-509

PubMed: 31940492 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 20;12(2) pii: E493

PubMed: 32093281 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

Virology, 2020, 539:1-10

PubMed: 31605941 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):617

PubMed: 32615946 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-10

PubMed: 32558607 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )
Cell Death Differ, 2020, 10.1038/s41418-020-0590-4

PubMed: 32694652 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30179-X

PubMed: 33161156 ( click the link to review the publication )

Clin Transl Med, 2020, 10.1002/ctm2.41

PubMed: 32508052 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1249-1260

PubMed: 31665637 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0338-1

PubMed: 31065106 ( click the link to review the publication )

Oncogene, 2019, 38(14):2501-2515

PubMed: 30532073 ( click the link to review the publication )

EBioMedicine, 2019, 45:251-260

PubMed: 31201144 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Oncologist, 2019, 24(7):989-996

PubMed: 31019022 ( click the link to review the publication )

Oncogenesis, 2019, 8(12):67

PubMed: 31732712 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(7):4545-4558

PubMed: 31062473 ( click the link to review the publication )

Mol Immunol, 2019, 108:68-74

PubMed: 30784764 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1075-1082

PubMed: 30535478 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

Sci Adv, 2018, 4(12):eaat5077

PubMed: 30585287 ( click the link to review the publication )

Cell Rep, 2018, 22(12):3206-3216

PubMed: 29562177 ( click the link to review the publication )

EBioMedicine, 2018, 36:252-265

PubMed: 30274821 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):168

PubMed: 29416011 ( click the link to review the publication )

Oncogenesis, 2018, 7(3):33

PubMed: 29593251 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):7424-7434

PubMed: 29663367 ( click the link to review the publication )

EMBO J, 2017, 36(23):3483-3500

PubMed: 29046333 ( click the link to review the publication )

Leukemia, 2017, 31(6):1296-1305

PubMed: 27885271 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3130

PubMed: 29048401 ( click the link to review the publication )
Sci Rep, 2017, 7(1):16652

PubMed: 29192272 ( click the link to review the publication )

FEBS Lett, 2017, 591(18):2905-2918

PubMed: 28670683 ( click the link to review the publication )

Journal of Functional Foods, 2017, 31:217-228

PubMed: None ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Mol Cell, 2016, 63(3):526-38

PubMed: 27453044 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Med Oncol, 2016, 33(10):113

PubMed: 27586146 ( click the link to review the publication )

Hepatology, 2015, 62(5):1497-510

PubMed: 26173433 ( click the link to review the publication )

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

Sci Rep, 2015, 5:8202

PubMed: 25644037 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.29194

PubMed: 25196217 ( click the link to review the publication )

Int J Oncol, 2014, 45(2):675-82

PubMed: 24867259 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):761-8

PubMed: 24366007 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1305-15

PubMed: 25122426 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Transl Oncol, 2013, 6(6):685-96

PubMed: 24466371 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e294

PubMed: 22476102 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e243

PubMed: 22170099 ( click the link to review the publication )

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述

Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。

靶点

Mdm2 ^[5]
(Cell-free assay)

180 nM

体外研究

Nutlin-3有效抑制MDM2-p53相互作用，IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞，如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性，IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时，显著诱导caspase依赖的细胞凋亡，凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力，IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力，而3 μM Nutlin-3 处理SJSA-1细胞后，细胞则无活力。^[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化，在特定DNA结合序列没有区别，且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比，使p53靶点基因转活，说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。^[2] 虽然与MDM2相比，Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1)，能抑制MDMX–p53相互作用，且诱导 p53通路，IC50为0.7 μM。^[3] 30 μM Nutlin-3作用于无野生型p53的细胞，也扰乱内源性p73-HDM2 相互作用，且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制，和诱导凋亡。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SMMC-7721	MVrGeY5kfGmxbjDBd5NigQ>?	NIL4WmEyOCEQvF2=	MY[zOkBp	NXe0NYt1TE2VTx?=	M4P5eYRwf25vcnXneYxifGW\|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ\|OUKtdFU{	NYrkcZF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
HuH-7	NH7lRodCeG:ydH;zbZMhSXO\|YYm=	NX7rTY5SOjBizszN	MY[0PEBp	NILjS2lFVVOR	NFHsdm9qdmS3Y3XzJIFxd3C2b4Ppdy=>	MknFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OE[zNVIoRjJ2Mki2N\|EzRC:jPh?=
SMMC-7721	MlTSRZBweHSxc3nzJGF{e2G7	NYLWdGZKOjBizszN	NGTmbHg1QCCq	MnrkSG1UVw>?	MnjFbY5lfWOnczDhdI9xfG:\|aYO=	M4nB[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki2N\|EzLz5{NEK4OlMyOjxxYU6=
HuH-7	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHHZXHEyNjJ3LUKwJO69VQ>?	MVKyOE81QC95MjDo	MYPEUXNQ	NX\nbW1lcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk>	NHrrb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
SMMC-7721	MlG2R4VtdCCYaXHibYxqfHliQYPzZZk>	NXW3Soc{OS5{NT2yNEDPxE1?	M333UlI1NzR6L{eyJIg>	NXvjdXY{TE2VTx?=	MUfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OE[zNVIoRjJ2Mki2N\|EzRC:jPh?=
RKO	NXvBSYE{TnWwY4Tpc44hSXO\|YYm=	NWjl[Ws4OjBizszN	M1fCcFI1KGh?		M2PXe4lv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u	NYnQdm1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlYxODdpPkK0N\|Y3ODB5PD;hQi=>
U2OS	MoTMSpVv[3Srb36gRZN{[Xl?	NX7JWXY2OjBizszN	M{X3U\|I1KGh?		M2DlVolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u	NEXLVmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
RKO	NXryOG9pTnWwY4Tpc44hSXO\|YYm=	MYWyNEDPxE1?	MVWyOEBp		MYDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG\|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv	MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|Nk[wNFcoRjJ2M{[2NFA4RC:jPh?=
U2OS	Ml7iSpVv[3Srb36gRZN{[Xl?	NFrOfFgzOCEQvF2=	M3L5T\|I1KGh?		NUf5fm4{cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?=	NHLtOZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
MOLM	NXjSeVJCTnWwY4Tpc44hSXO\|YYm=	NGL6S2syOCEQvF2=	NWHyeWpYOjRiaB?=		MXr1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5M{W2Nkc,OjR2N{O1OlI9N2F-
OCI	MmXISpVv[3Srb36gRZN{[Xl?	MofmNVAh\|ryP	MoXuNlQhcA>?		MUT1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5M{W2Nkc,OjR2N{O1OlI9N2F-
BeWo	M2PSW2Fxd3C2b4Ppd{BCe3OjeR?=	MXezNEDDvU1?	M3PjbFI1KGh?		MUPpcoNz\WG\|ZYOgZZBweHSxc3nz	M4fSVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm4NVU1Lz5{NES5PFE2PDxxYU6=
BeWo	M3v2R2Z2dmO2aX;uJGF{e2G7	MUmzNEDDvU1?	MXSyOEBp		MVTpcoNz\WG\|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7OEG1OEc,OjR2OUixOVQ9N2F-
MOML13	M1;YNGZ2dmO2aX;uJGF{e2G7	MV6xNO69VQ>?	MUiyM\|QhcA>?		NYjiNY9ncW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3OUe0PUc,OjR4NUm3OFk9N2F-
AML3	NFjLUWFHfW6ldHnvckBCe3OjeR?=	MV6xNO69VQ>?	MkfCNk81KGh?		NGn1cphqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=>	NELNXIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1PVc1QSd-MkS2OVk4PDl:L3G+
AML2	M1nvW2Z2dmO2aX;uJGF{e2G7	NGfwTZAyOM7:TR?=	M{DTb\|IwPCCq		NFHHS3dqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=>	MknrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O\|Q6RC:jPh?=
MOML13	MoDhRZBweHSxc3nzJGF{e2G7	MmDNNk8yOCEQvF2=	MXSyOE81QCCq		M3XWXIlv\HWlZYOgZZBweHSxc3nz	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3OUe0PUc,OjR4NUm3OFk9N2F-
AML2	MkX1RZBweHSxc3nzJGF{e2G7	MUiyM\|ExKM7:TR?=	NFPO[5YzPC92ODDo		M{fpdYlv\HWlZYOgZZBweHSxc3nz	Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O\|Q6RC:jPh?=
U2OS	Mn\USpVv[3Srb36gRZN{[Xl?	MWiyNEDPxE1?	M1S5W\|I1KGh?		NX7UNHRucW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4N{K1PUc,OjR6NkeyOVk9N2F-
Hep3B	MX7BdI9xfG:\|aYOgRZN{[Xl?				MXfpcoR2[2W\|IHHwc5B1d3Orcx?=	NFfLZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
Huh-7	NIXsPZlCeG:ydH;zbZMhSXO\|YYm=				MWPpcoR2[2W\|IHHwc5B1d3Orcx?=	NXn5dpozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
SMMC7721	MnnqRZBweHSxc3nzJGF{e2G7				MYDpcoR2[2W\|IHHwc5B1d3Orcx?=	NVi0WXRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
HepG2	MWLBdI9xfG:\|aYOgRZN{[Xl?				M{jJeIlv\HWlZYOgZZBweHSxc3nz	NF2xZ2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
Hep3B	M4qyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV3LTGJsPzJiaB?=	MlWySG1UVw>?	MWHJR\|UxRTJyLkG4JOKyKDFwOESg{txO	Mm\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
Huh-7	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVu3NkBp	NXvoZWxiTE2VTx?=	Ml7mTWM2OD1\|Mz65OkDDuSB\|Lkmg{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
SMMC7721/Ac	M13l[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFq3PJU4OiCq	MlPOSG1UVw>?	Mn\ITWM2OD13NT6yNUDDuSB3LkCzJO69VQ>?	NW\mVZZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
SMMC7721	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\iSVczKGh?	MXXEUXNQ	MlL1TWM2OD1\|MT6yPEDDuSB2LkKg{txO	MnnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
HepG2/As	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3zkO\|czKGh?	Mn\ZSG1UVw>?	NIHwVppKSzVyPU[4MlE{KMLzIEmuOkDPxE1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
HepG2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jMTVczKGh?	NGXsNFFFVVOR	Ml25TWM2OD1\|NT64OkDDuSB{Lkmg{txO	NYriN4R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
MOLM-13	M{\VWWZ2dmO2aX;uJGF{e2G7	MlHUOuKh\|ryP	MmTrOkBp	NILrOYpFVVOR	NVnDO4Q3\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi\|cEK3JIFv\CCKc4C5NC=>	M1\6TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi1NFgzLz5{NEi4OVA5OjxxYU6=
MOLM-13	MV3GeY5kfGmxbjDBd5NigQ>?	M3rnb\|bDqM7:TR?=	MXWwMVghcA>?	M3qxVGROW09?	NXHZTFFncW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV\|	NYLBTYE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFUxQDJpPkK0PFg2ODh{PD;hQi=>
115	NIL6ZZZHfW6ldHnvckBCe3OjeR?=	M3i5SFUh\|ryP	NVfsV3JiPDhiaB?=	MknTSG1UVw>?	NHK1[IhqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg	M3\ZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
A498	M2HTOmZ2dmO2aX;uJGF{e2G7	Mn;MOUDPxE1?	MoT0OFghcA>?	NUOwT2hyTE2VTx?=	MWPpcoR2[2W\|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi	NUSzVVZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2	NVzrcWpKTnWwY4Tpc44hSXO\|YYm=	NVmzSmNUPSEQvF2=	M{K3c\|Q5KGh?	NX3yOmZjTE2VTx?=	NXz0O4J4cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
ACHN	M4HpRmZ2dmO2aX;uJGF{e2G7	M3HFSFUh\|ryP	M3juW\|Q5KGh?	MXXEUXNQ	NEeydYJqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O\|g4RC:jPh?=
115	NHvVbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIi0[Yo2KM7:TR?=	MVm0PEBp	MUfEUXNQ	NYLlXo5jcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
A498	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnzOUDPxE1?	M1PsbVQ5KGh?	MW\EUXNQ	MWDpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2wrC=	NXu5T3Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2	M2naVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW0OUDPxE1?	MYK0PEBp	MoXtSG1UVw>?	M2DtOIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=>	NWHOTppqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
ACHN	NIHCVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVq1JO69VQ>?	MnTROFghcA>?	MX7EUXNQ	MojObY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dNMg	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
115	NGnYUIFHfW6ldHnvckBCe3OjeR?=	NGTsNWMxNjVxMT:1JO69VQ>?	NUL2Z\|M5PDhiaB?=	NHi5TIZFVVOR	NH3pdmFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV\|IIThdodmfCCpZX7ld\|ohVUSPMjygZY5lKHB{MR?=	M3TH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
A498	NUnhSFJGTnWwY4Tpc44hSXO\|YYm=	MWOwMlUwOS93IN88US=>	NVTpS5h3PDhiaB?=	NIfHVmJFVVOR	M1PtO4xm[WS\|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz	NG\VZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O\|c5Pyd-MkWwOlc4QDd:L3G+
Caki-2	NHH2V2lHfW6ldHnvckBCe3OjeR?=	M2DXW\|AvPS9zL{Wg{txO	NVnPbFZ1PDhiaB?=	NUTuPVNWTE2VTx?=	MlHncIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC\|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF?	M2THS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
ACHN	MkTUSpVv[3Srb36gRZN{[Xl?	MXSwMlUwOS93IN88US=>	NGnzSHY1QCCq	NET3cppFVVOR	Mlz4cIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC\|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
117	M3jseGNmdGxiVnnhZoltcXS7IFHzd4F6	NWXBclczOC53LUGwJO69VQ>?	MUewMVYh\A>?	MnzZSG1UVw>?	NXvyNHZrcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3vDdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
115	M2XMd2NmdGxiVnnhZoltcXS7IFHzd4F6	NGjRe\|kxNjVvMUCg{txO	M2r6W\|AuPiCm	MnfKSG1UVw>?	MXLpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2jFcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
A498	NVvZO4ZmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWHiWVZ2OC53LUGwJO69VQ>?	MnexNE03KGR?	MYnEUXNQ	MWTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NYXWNWRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2	M3\rUmNmdGxiVnnhZoltcXS7IFHzd4F6	NV:3SHgzOC53LUGwJO69VQ>?	NHfERVAxNTZiZB?=	MoP0SG1UVw>?	MUfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M4Hx[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O\|g4Lz5{NUC2O\|c5PzxxYU6=
ACHN	NF7jeWlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3fvOlAvPS1zMDFOwG0>	NEfOPXoxNTZiZB?=	MXHEUXNQ	NW\qNIhGcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MkPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O\|g4RC:jPh?=
MCF7	M4fkUmZ2dmO2aX;uJGF{e2G7	NW\qVW9HOi53INM1US=>	NUHJN\|Z[PDhiaB?=	M3\CNmROW09?	Mn3w[IVkemWjc3XzJJRp\SCqb33vcI9od3W\|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM>	NVjIXpBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFU6ODJpPkK1NFg2QTB{PD;hQi=>
MCF7	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXHGTW5yOi53INM1US=>	M1rHNFUh\A>?	NUnW[Fg1TE2VTx?=	MXXz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w	NFHNc\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4OVkxOid-MkWwPFU6ODJ:L3G+
RAW 264.7	MlHzSpVv[3Srb36gRZN{[Xl?	MkCzNVDDqM7:TR?=	MXyzNEBucW5?		Mn3XbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg	M4i3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOVQ4Lz5{NUG3NlU1PzxxYU6=
RAW 264.7	NEezeIdHfW6ldHnvckBCe3OjeR?=	NVr3VWdnOTEEoN88US=>	M1PEZVMxKG2rbh?=		MVXy[YR2[2W\|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkW0O{c,OjVzN{K1OFc9N2F-
RAW 264.7	NIjYVpRHfW6ldHnvckBCe3OjeR?=	MknZNVDDqM7:TR?=	Ml\MN\|AhdWmw		Mlf0dJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW\|cH;ud4UhfG9iTGDT	M{TIb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOVQ4Lz5{NUG3NlU1PzxxYU6=
SUM102PT	MV;GeY5kfGmxbjDBd5NigQ>?	M{\QWVExyqEQvF2=	NYm3RZR7OjRiaB?=	MYLEUXNQ	M1rCVYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	M3nwN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3O\|I6Lz5{NUK1O\|czQTxxYU6=
SK-BR-7	NHGwdJdHfW6ldHnvckBCe3OjeR?=	MXqxNOKh\|ryP	M333XVI1KGh?	NHfFNW5FVVOR	NGXj[o9qdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	NGflZ4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1O\|czQSd-MkWyOVc4Ojl:L3G+
MCF-10CA1a	MlvGSpVv[3Srb36gRZN{[Xl?	NH;UPZEyOMLizszN	NEPETZgzPCCq	MVTEUXNQ	NHfyXWRqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O\|I6RC:jPh?=
MCF-10CA1a	MV3GeY5kfGmxbjDBd5NigQ>?	NXLKcI5xOTEEoN88US=>	M3\DNVI1KGh?	MUDEUXNQ	NXHkWWQ6\GWlcnXhd4V{KHSqZTDUS2Yu\|rJ\|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh\|rMEoEO=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10A1	M3z1TGZ2dmO2aX;uJGF{e2G7	M1jVXlExyqEQvF2=	M3;OOFI1NzR6IHi=	M3HmW2ROW09?	MXfpcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG\|dDDldIl1cGWuaXHsxsA>	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O\|I6RC:jPh?=
MCF-10CA1a	MlrQSpVv[3Srb36gRZN{[Xl?	M4HhelExyqEQvF2=	MVy0PEBp	MXPEUXNQ	MVPpcohq[mm2czDiZZNidCCrbo\hd4lwdiCjbnSgdoVlfWOnZDDUS2Yu\|rJ\|LXnu[JVk\WRiaX72ZZNqd25idH:gZoF{[WxibHX2[Yx{	NEHJRYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1O\|czQSd-MkWyOVc4Ojl:L3G+
HCT116	M2nicWZ2dmO2aX;uJGF{e2G7	MkLONVAhyrWP	MXKyOEBp		NWfy[WFQ[2G3c3XzJIEheDV\|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4	NX;VN3VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFAxPTVpPkK1N\|gxODV3PD;hQi=>
A2780	M4\KVmZ2dmO2aX;uJGF{e2G7	NH;COXEyOMLizszN	NHvtWmQzOWkEoB?=	M2W4ZWROW09?	M{jsSYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz	M17GVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
NCI-H23	MXnGeY5kfGmxbjDBd5NigQ>?	MnLwNVDDqM7:TR?=	NFXENHYzOWkEoB?=	NEjVb3BFVVOR	M2PYfIRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz	M2XGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
A2780	NHfDbpVHfW6ldHnvckBCe3OjeR?=	NGD4dGEyOMLizszN	MV:yNYjDqA>?	M4Hle2ROW09?	NX3pXWhDcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
NCI-H23	NH3PeGtHfW6ldHnvckBCe3OjeR?=	NVjM[3A5OTEEoN88US=>	M4Xqb\|IycMLi	MVfEUXNQ	NYi0XJVocW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>?	NHW2TYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOlU1QCd-MkW0NlY2PDh:L3G+
OVCAR10	NUTFT\|hCTnWwY4Tpc44hSXO\|YYm=	M1jJXFExyqEQvF2=	MmTCNlFpyqB?	MWPEUXNQ	MmLtbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=>	M131elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
MCF-7	M3XmXWZ2dmO2aX;uJGF{e2G7	NXjVdodHOTEEoN88US=>	NH\UUG4xNTJ2IHi=		NUDOSZNMcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MkO3N{c,OjV2OEKzO\|M9N2F-
SMMC-7721	MmXYSpVv[3Srb36gRZN{[Xl?	MWmxNEDPxE1?	M2\nOVM3KGh?	MYPEUXNQ	M{PxUoNifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3	NWHaTWJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OFQ{PjFpPkK1OVQ1OzZzPD;hQi=>
SMMC-7721	M3fvU2Z2dmO2aX;uJGF{e2G7	NE\ibJUyOCEQvF2=	MofLOFghcA>?	NFXnOWZFVVOR	Moq3bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=>	MnywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NESzOlEoRjJ3NUS0N\|YyRC:jPh?=
SMMC-7721	MUnGeY5kfGmxbjDBd5NigQ>?	NXn6S\|FVOTBizszN	MmjDOFghcA>?	NXPvb\|U{TE2VTx?=	MofzbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=>	MlzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NESzOlEoRjJ3NUS0N\|YyRC:jPh?=
SMMC-7721	NWHDOJJTTnWwY4Tpc44hSXO\|YYm=	NFzvfJgyOCEQvF2=	M1XrSVQ5KGh?	NXXDWZpHTE2VTx?=	MXvjZZV{\XNiRF7BJGRUSiCmYX3h[4U>	NHTac5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
DU4475	MniwSpVv[3Srb36gRZN{[Xl?	MXO1M\|ExNzJyIN88US=>	Mk[yNlTDqGh?		M4L0TIRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk>	NGC5bYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0O\|E4PCd-MkW1OFcyPzR:L3G+
MCF-7	NHuzT\|VHfW6ldHnvckBCe3OjeR?=	NHztbncyOMLizszN		MorDSG1UVw>?	M4L1dIlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>?	NX\MdYZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFI4ODNpPkK1O\|AzPzB\|PD;hQi=>
C2C12	M3LycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXRZ3hEOTEEoN88UeKh	MVSyOE81QC95MjDo	NI[3eZlFVVOR	NYr2OIZJcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5MUe5OEc,OjV6N{G3PVQ9N2F-
L6	M3vjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYixNOKh\|ryPwrC=	M{jCNFI1NzR6L{eyJIg>	NXnGUlBpTE2VTx?=	NFX3[oxqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25?	NIDwbm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3NVc6PCd-MkW4O\|E4QTR:L3G+
CRL-5908	NVTLPJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoLsNlQhcA>?		NX22OFVoUUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN\|A9N2F-
A549-920	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHy4WZQzPCCq		MYLJR\|UxRTN\|Lki1JOKyKDRwOESg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN\|A9N2F-
A549-NTC	NFTqdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MW[yOEBp		NUfEW49LUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?=	MnrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkWyN\|AoRjJ4MUK1NlMxRC:jPh?=
A549	M2\3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmfpNlQhcA>?		NFizNpRKSzVyPUG3MlY5KMLzIESuOVIh\|ryP	M{LM[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1NlMxLz5{NkGyOVI{ODxxYU6=
C666-1	MlfnRZBweHSxc3nzJGF{e2G7	NX3oUnRUOTBiwsXN	MUe0PE84OiCq	MmfGSG1UVw>?	NH7KPHR{\W6\|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O\|UoRjJ4MkWyOVc2RC:jPh?=
C666-1	NGDKZWxHfW6ldHnvckBCe3OjeR?=	NH;JVVAyOCEEtV2=	NUD6fGN6OjRiaB?=	M4WxbmROW09?	MmPSZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3MkW3OUc,OjZ{NUK1O\|U9N2F-
C666-1	NYL4W2tsS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWPxflJNOTBiwsXN	M3HsW\|Q5KGh?	M{C4cmROW09?	NHHHXXl{\W6\|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6=	NFXKNGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NlU4PSd-Mk[yOVI2PzV:L3G+
C666-1	M2Hn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PMZmlEPTB;MUmuPVXDuThwOUOg{txO	NVv3b2JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
NP460	NX[xRYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTWTWM2OD1{Mj64OeKyOS5zODFOwG0>	NYLHUnl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
NP69	NXTmUWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;OTWM2OD1\|MT62PeKyOi53NDFOwG0>	NYC4N4Q4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
MCF7	NUPTfnlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn5eJM5PcLizszN	NUXYWnBVPDkEoHi=		Ml\iZoxw[2u\|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{	NFPH[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NFU3PSd-Mk[zOVA2PjV:L3G+
HuH-7	NYD5R4R4TnWwY4Tpc44hSXO\|YYm=	NWHZeGt3OTBizszN	MUKzOkBp	MnHESG1UVw>?	Mn;z[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW\|c3nvckBt\X[nbDDv[kBxcG:\|cHjvMXNmejN7Mj3wOVM>	NYrlOYtXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
AT2	NWPiSG0yTnWwY4Tpc44hSXO\|YYm=	M1ThRVUwOTBizszN			NF21bodt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW\|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
REH	MUnGeY5kfGmxbjDBd5NigQ>?	NFLrW242NzFyIN88US=>			NYXsZWNidGWjZIOgeI8h[SC\|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG\|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS\|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6\|wrC=	NX3BZ4t5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB\|PD;hQi=>
UoCB6	M3TzeGZ2dmO2aX;uJGF{e2G7	NHX5[Hc2NzFyIN88US=>			M{fJ[Yxm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO\|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li	NH3peWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NFIxOyd-MkSyOFAzODN:L3G+
AT2	NIfj[lFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NInqRo8xNTJ3IN88US=>			MWXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NYnKOJRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB\|PD;hQi=>
REH	NFSzT3pE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVewMVI2KM7:TR?=			MkG4bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
UoCB6	NYXEUZRFS2WubDDWbYFjcWyrdImgRZN{[Xl?	NXvhblBNOC1{NTFOwG0>			MlvObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NEHEPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NFIxOyd-MkSyOFAzODN:L3G+
A2780	NEnObpJHfW6ldHnvckBCe3OjeR?=	NHH2SHQ2NzFyL{KwJO69VQ>?	MVKyOEBp		NYjYe5BCfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC=	M2TOe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
H460	MlfISpVv[3Srb36gRZN{[Xl?	M3q1elUwOTBxMkCg{txO	NFrVRlQzPCCq		MmnKeZBz\We3bHH0[ZMheDV\|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB?	NGfoeFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOlE1Pyd-MkSxN\|YyPDd:L3G+
Lovo	NWrSS3lETnWwY4Tpc44hSXO\|YYm=	NV3tNVI5PS9zMD:yNEDPxE1?	MUWyOEBp		MlXveZBz\We3bHH0[ZMheDV\|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB?	NXXNS5RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|YyPDdpPkK0NVM3OTR5PD;hQi=>
A2780	M4TzNmFxd3C2b4Ppd{BCe3OjeR?=	M1nTeFUwOTBxMkCg{txO	NUjoWmdCOjRiaB?=		NG[zb5VmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>?	MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
H460	MXHBdI9xfG:\|aYOgRZN{[Xl?	M{TycVUwOTBxMkCg{txO	M4HnWlI1KGh?		NYPHZoF5\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx?	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
Lovo	NGXZVWxCeG:ydH;zbZMhSXO\|YYm=	MkG3OU8yOC9{MDFOwG0>	M{LmU\|I1KGh?		NVi2WJhR\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx?	MmLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
U87MG	NGS4OoxHfW6ldHnvckBie3OjeR?=		MoTMNVAhdWmwcx?=		NYT6W\|BYSmmwZHnu[{Bi\m[rbnn0fUB1dyCPRF2yJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVUSPMj;wOVMheHKxdHXpckBqdnSncnHjeIlwdiCjZoTldkAyOCCvaX7zJIJ6KHG3YX70bZRifGm4ZTDzZY5lf2mlaDDpcY12dm9iYYPzZZktKEmFNUCgQUAxNjFyNEWg{txONg>?	NHTFVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C1NFc5Oid-MkewOVA4QDJ:L3G+
U87MG	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXO0PEBpenN?		NIrhSJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKHB3MzDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNj61JO69VS5?	NH\teZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C1NFc5Oid-MkewOVA4QDJ:L3G+
U343MG	NHPmN5FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWDsUW97PDhiaILz		NHq4eoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWzOFNOTyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCyNUOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEGyMlYh\|ryPLh?=	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNUC3PFIoRjJ5MEWwO\|gzRC:jPh?=
SW620	M2jlOmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NED0fXM4OiCqcoO=		NHS1S3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5\|ODFOwG0v	NWq3[FRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
A549	MnfBR5l1d3SxeHnjbZR6KGG\|c3H5		MYS3NkBpenN?		MmTDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE41OSEQvF2u	M4SxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE6OTN\|ND:nQmNpTU2ETEyvZV4>
SJSA1	NFTvV2hEgXSxdH;4bYNqfHliYYPzZZk>		M33kd\|czKGi{cx?=		M37m[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNLW0FzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAyNjhzIN88UU4>	NXTqPJVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
HCT116	NUW1WmhGS3m2b4TvfIlkcXS7IHHzd4F6		M2HLflczKGi{cx?=		NHrWOphEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDRwNkOg{txONg>?	M3zTU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE6OTN\|ND:nQmNpTU2ETEyvZV4>
PC3	MkX1R5l1d3SxeHnjbZR6KGG\|c3H5		NYjISlAzPzJiaILz		M4SzfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOk4{PyEQvF2u	MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MDM2 / p53 / ALKBH2 / p21 / PUMA; PubMed: 23258843 Neuro Oncol CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting. RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; PubMed: 28507282 Oncotarget (A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.	23258843 28507282
Immunofluorescence	Lamin A / Lamin C / p16 / H3K9me3; PubMed: 30728349 Cell Death Dis c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. Merlin / cyclin D1 / p53 / MDM2; PubMed: 30274821 EBioMedicine The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm. p53; PubMed: 24286312 BMB Rep The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).	30728349 30274821 24286312
Growth inhibition assay	Cell viability; PubMed: 29286113 Mol Med Rep Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.	29286113

体内研究

Nutlin-3 按200 mg/kg 剂量口服处理，每天两次，持续3周，显著抑制SJAS-1移植瘤生长，抑制达90%, 而Doxorubicin抑制81%肿瘤生长。^[1]

激酶实验： ^[1]	- 合并 Biacore 研究: 在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5，用于固定 PentaHis抗体，为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm²)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO，浓度为10 mM，然后进一步稀释，在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25^oC下进行实验。在Nutlin-3存在时，计算MDM2-p53结合情况，作为结合百分数，使用Microsoft Excel计算IC50。
细胞实验： ^[1]	- 合并 Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435 Concentrations: 溶于DMSO,终浓度为~ 30 μM Incubation Time: 8, 24, 和 48 小时 Method: 使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法（TUNEL）染色，使用流式细胞仪和荧光显微镜测定细胞凋亡。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠 Dosages: 200 mg/kg Administration: 口服处理，每天两次 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (171.96 mM)
	Ethanol	30 mg/mL (51.59 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Nutlin-3 SDF

分子量	581.5
化学式	C₃₀H₃₀Cl₂N₄O₄
CAS号	890090-75-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?
回答：
It is a racemate.

研究领域

产品类型

定制您的化合物库

Nutlin-3

客户使用Selleck生产的Nutlin-3发表文献68篇：

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Nutlin-3 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Mdm2 Signaling Pathway Map

相关Mdm2产品